drugset / Trial / NCT04288518
Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
Phase 1/2
Completed
16 enrolled
Tomsk National Research Medical Center of the Russian Academy of Sciences
Uppsala University · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The study should evaluate the biological distribution of 99mTc-1-thio-D-glucose in patients with primary brain tumors and recurrence of brain tumors. The primary objective are: 1. To assess the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc-1-thio-D-glucose. 3. To study the safety and tolerability of the drug 99mTc-1-thio-D-glucose after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained SPECT imaging results of brain tumors with the data of magnetic resonance imaging (MRI) and/or positron emission tomography (PET) and immunohistochemical (IHC) studies of postoperative material.
Timeline
- Start
- 2020-02-15
- Primary completion
- 2021-02-15
- Completion
- 2021-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 99mTc-1-thio-D-glucose | Diagnostic / imaging agent | 500 mbq | Intravenous |